Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants
Université Laval
$60,000.00
Characterization of PTM-associated mutations that alter signaling network in breast and ovarian cancers.
FY 2018-19
Summary
Cancer is a widespread disease and Canadians have ~40% chance of being diagnosed with cancer during their life. Although the last years have witnessed the development of therapies that precisely kill certain types of cancer cells, we still struggle to identify the groups of patients that would benefit from specific treatments. Here, we propose to interpret mutations in two well-known cancer genes that determine how breast and ovarian cancers respond to therapies. By combining our expertise in computational data analysis and cellular biology, we study large molecular datasets of cancers from patients and perform cell biology experiments to define how the mutations alter cancer cells and their response to therapies. Knowledge from our work may help to select patients that are likely to respond to a particular treatment. Globally, we expect that our research will contribute to our knowledge of the unique biology of breast and ovarian cancers and enable better treatment regimens that rely on the patient’s genome information to provide personalized therapies.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
407419
Name
Fradet-Turcotte Amélie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Characterization of PTM-associated mutations that alter signaling network in breast and ovarian cancers.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Breast Cancer
Abstract
Cancer is a widespread disease and Canadians have ~40% chance of being diagnosed with cancer during their life. Although the last years have witnessed the development of therapies that precisely kill certain types of cancer cells, we still struggle to identify the groups of patients that would benefit from specific treatments. Here, we propose to interpret mutations in two well-known cancer genes that determine how breast and ovarian cancers respond to therapies. By combining our expertise in computational data analysis and cellular biology, we study large molecular datasets of cancers from patients and perform cell biology experiments to define how the mutations alter cancer cells and their response to therapies. Knowledge from our work may help to select patients that are likely to respond to a particular treatment. Globally, we expect that our research will contribute to our knowledge of the unique biology of breast and ovarian cancers and enable better treatment regimens that rely on the patient’s genome information to provide personalized therapies.
Competitiondate
201902
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Fradet-Turcotte, Amélie
Approvedterm
2 ans 0 mois
Cihrcontribution2
Breast Cancer Initiative~ $60,000~ $0~